STAT6 promotes bi-directional modulation of PKM2 in liver and adipose inflammatory cells in Rosiglitazone-treated mice

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Sajic, Tatjana ^a   Hainard, Alexandre ^a   Scherl, Alexander ^a   Wohlwend, Annelise ^a   Negro, Francesco ^b   Sanchez, Jean Charles ^a   Szanto, Ildiko ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CARRIER PROTEIN; MEMBRANE PROTEIN; PROTEOME; ROSIGLITAZONE; STAT6 PROTEIN; STAT6 PROTEIN, MOUSE; THYROID HORMONE; THYROID HORMONE BINDING PROTEINS; THYROID HORMONE-BINDING PROTEINS;

ADIPOSE TISSUE; ANIMAL; ARTICLE; CYTOLOGY; DRUG EFFECT; KNOCKOUT MOUSE; LIVER; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; DRUG EFFECTS;

ADIPOSE TISSUE; ANIMALS; CARRIER PROTEINS; LIVER; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PROTEOME; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; THYROID HORMONES;

EID: 84881454606     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02350     Document Type: Article

References (57)

1. Hebenstreit, D., Wirnsberger, G., Horejs-Hoeck, J. & Duschl, A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 17, 173-188 (2006). (Pubitemid 43816893)
2. Takeda, K., Kishimoto, T. & Akira, S. STAT6: its role in interleukin 4-mediated biological functions. J Mol Med 75, 317-326 (1997). (Pubitemid 27247963)
3. Kaplan, M. H., Schindler, U., Smiley, S. T. & Grusby, M. J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4, 313-319 (1996). (Pubitemid 26132509)
4. Tomkinson, A. et al. The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med 160, 1283-1291 (1999). (Pubitemid 29487472)
5. Goenka, S. & Kaplan, M. H. Transcriptional regulation by STAT6. Immunol Res (2011).
6. Odegaard, J. I. & Chawla, A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 4, 619-626 (2008).
7. Szanto, A. et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity 33, 699-712 (2010).
8. Mishra, B. B., Gundra, U. M. & Teale, J. M. STAT6(-/-) mice exhibit decreased cells with alternatively activated macrophage phenotypes and enhanced disease severity in murine neurocysticercosis. J Neuroimmunol 232, 26-34 (2011).
9. Ricardo-Gonzalez, R. R. et al. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc Natl Acad Sci USA 107, 22617-22622 (2010).
10. Iff, J. et al. Differential proteomic analysis of STAT6 knockout mice reveals new regulatory function in liver lipid homeostasis. J Proteome Res 8, 4511-4524 (2009).
11. Odegaard, J. I. et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007). (Pubitemid 47014427)
12. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72, 219-246 (2010).
13. Bensinger, S. J. & Tontonoz, P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454, 470-47 (2008).
14. Chawla, A. Control of macrophage activation and function by PPARs. Circ Res 106, 1559-1569 (2010).
15. Odegaard, J. I. & Chawla, A. Alternative macrophage activation and metabolism. Annu Rev Pathol 6, 275-297 (2011).
16. Hotamisligil, G. S. & Spiegelman, B. M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43, 1271-1278 (1994).
17. Yeh, M. M. & Brunt, E. M. Pathology of nonalcoholic fatty liver disease. American journal of clinical pathology 128, 837-84 (2007).
18. Mayerson, A. B. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797-802 (2002). (Pubitemid 34760191)
19. Juurinen, L., Kotronen, A., Graner, M. & Yki-Jarvinen, H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. The Journal of clinical endocrinology and metabolism 93, 118-124 (2008).
20. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D. & Bacon, B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008-101 (2003).
21. Sanchez, J. C. et al. Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics 3, 1500-1520 (2003).
22. Ackerman, Z. et al. Hepatic effects of rosiglitazone in rats with the metabolic syndrome. Basic Clin Pharmacol Toxicol 107, 663-668 (2010).
23. Hockings, P. D. et al. Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats. Diabetes Obes Metab 5, 234-243 (2003). (Pubitemid 36806127)
24. Thompson, A. et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 75, 1895-1904 (2003). (Pubitemid 36438013)
25. Dayon, L. et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 80, 2921-2931 (2008). (Pubitemid 351556457)
26. Mazurek, S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol, (2010).
27. Mazurek, S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc, 99-124 (2007).
28. Panasyuk, G. et al. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat Commun 3, 672 (2012).
29. Fujisaka, S. et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58, 2574-2582 (2009).
30. Nishimura, S. et al. CD81 effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15, 914-920 (2009).
31. Baratta, J. L. et al. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. Histochem Cell Biol 131, 713-726 (2009).
32. Friedman, S. L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88, 125-172 (2008).
33. Dhawan, M. et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol 34, 582-584 (2002). (Pubitemid 34429423)
34. Vats, D. et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell metabolism 4, 13-24 (2006). (Pubitemid 43942258)
35. Johnson, J. A., Trasino, S. E., Ferrante, A. W., Jr. & Vasselli, J. R. Prolonged decrease of adipocyte size after rosiglitazone treatment in high-and low-fat-fed rats. Obesity (Silver Spring) 15, 2653-2663 (2007).
36. MacKellar, J., Cushman, S. W. & Periwal, V. Differential effects of thiazolidinediones on adipocyte growth and recruitment in Zucker fatty rats. PloS one 4, e8196 (2009).
37. Shoelson, S. E., Lee, J. & Goldfine, A. B. Inflammation and insulin resistance. The Journal of clinical investigation 116, 1793-1801 (2006). (Pubitemid 44033299)
38. Foryst-Ludwig, A. et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovascular diabetology 9, 64 (2010).
39. Murphy, K. M. & Reiner, S. L. The lineage decisions of helper T cells. Nature reviews. Immunology 2, 933-944 (2002). (Pubitemid 37323214)
40. Nemolato, S. et al. Different thymosin Beta 4 immunoreactivity in foetal and adult gastrointestinal tract. PloS one 5, e9111 (2010).
41. Yoon, S. Y. et al. Thymosin beta4 expression correlates with lymph node metastasis through hypoxia inducible factor-alpha induction in breast cancer. Oncol Rep 25, 23-31 (2011).
42. Mazurek, S., Boschek, C. B., Hugo, F. & Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15, 300-308 (2005). (Pubitemid 41058775)
43. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat Rev Cancer 11, 85-95 (2011).
44. Pelicano, H., Martin, D. S., Xu, R. H. & Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633-4646 (2006). (Pubitemid 44187614)
45. Munoz-Pinedo, C., El Mjiyad, N. & Ricci, J. E. Cancer metabolism: current perspectives and future directions. Cell Death Dis 3, e248 (2012).
46. Wang, R. & Green, D. R. The immune diet: meeting the metabolic demands of lymphocyte activation. F1000 biology reports 4, 9 (2012).
47. Shapiro, H., Lutaty, A. & Ariel, A. Macrophages, meta-inflammation, and immuno-metabolism. TheScientificWorldJournal 11, 2509-2529 (2011).
48. Kannan, L., Rath, N. C., Liyanage, R. & Lay, J. O., Jr. Effect of toll-like receptor activation on thymosin beta-4 production by chicken macrophages. Mol Cell Biochem 344, 55-63 (2010).
49. Sharma, A. M. & Staels, B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. The Journal of clinical endocrinology and metabolism 92, 386-395 (2007).
50. Kintscher, U. & Law, R. E. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. American journal of physiology. Endocrinology and metabolism 288, E287-291 (2005). (Pubitemid 40110633)
51. Bays, H., Mandarino, L. & DeFronzo, R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. The Journal of clinical endocrinology and metabolism 89, 463-478 (2004). (Pubitemid 38269844)
52. Yki-Jarvinen, H. Thiazolidinediones. The New England journal of medicine 351, 1106-1118 (2004).
53. Gavrilova, O. et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278, 34268-34276 (2003). (Pubitemid 37553270)
54. Norris, A. W. et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. The Journal of clinical investigation 112, 608-618 (2003). (Pubitemid 38056345)
55. Zhan, Y. T. & An, W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World journal of gastroenterology: WJG 16, 4652-4660 (2010).
56. Tan, H. T. et al. Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol Cell Proteomics 7, 1174-1185 (2008). (Pubitemid 351943963)
57. Li, Y. et al. Deficiency in the NADPH oxidase 4 predisposes towards diet-induced obesity. Int J Obes (Lond), (2012).